Evidence map›Paper›PMID 26834734›Full record

ArticleFrontiers in immunology2015

Receptor-Interacting Protein Kinase-2 Inhibition by CYLD Impairs Antibacterial Immune Responses in Macrophages.

Katharina Wex, Ursula Schmid, Sissy Just, Xu Wang, Rebecca Wurm, Michael Naumann, Dirk Schlüter, Gopala Nishanth

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Proximity labeling of thebioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. CYLD in health and disease.Disease models & mechanisms · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Katharina WexInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg , Magdeburg , Germany.
Ursula SchmidInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg , Magdeburg , Germany.
Sissy JustInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg , Magdeburg , Germany.
Xu WangInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg , Magdeburg , Germany.
Rebecca WurmInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg , Magdeburg , Germany.
Michael NaumannInstitute of Experimental Internal Medicine, Otto-von-Guericke University Magdeburg , Magdeburg , Germany.
Dirk SchlüterInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg, Magdeburg, Germany; Organ-Specific Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Gopala NishanthInstitute of Medical Microbiology and Hospital Hygiene, Otto-von-Guericke University Magdeburg, Magdeburg, Germany; Organ-Specific Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Otto-von-Guericke University Magdeburg · DEHelmholtz Centre for Infection Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Upon infection with intracellular bacteria, nucleotide oligomerization domain protein 2 recognizes bacterial muramyl dipeptide and binds, subsequently, to receptor-interacting serine/threonine kinase 2 (RIPK2), which activates immune responses via the nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) and extracellular signal-regulated kinase (ERK) pathways. Activation of RIPK2 depends on its K63 ubiquitination by E3 ligases, whereas the deubiquitinating enzyme A20 counter regulates RIPK2 activity by cleaving K63-polyubiquitin chains from RIPK2. Here, we newly identify the deubiquitinating enzyme CYLD as a new inhibitor of RIPK2. We show that CYLD binds to and removes K63-polyubiquitin chains from RIPK2 in Listeria monocytogenes (Lm) infected murine bone marrow-derived macrophages. CYLD-mediated K63 deubiquitination of RIPK2 resulted in an impaired activation of both NF-κB and ERK1/2 pathways, reduced production of proinflammatory cytokines interleukin-6 (IL-6), IL-12, anti-listerial reactive oxygen species (ROS) and nitric oxide (NO), and, finally, impaired pathogen control. In turn, RIPK2 inhibition by siRNA prevented activation of NF-κB and ERK1/2 and completely abolished the protective effect of CYLD deficiency with respect to the production of IL-6, NO, ROS, and pathogen control. Noteworthy, CYLD also inhibited autophagy of Listeria in a RIPK2-ERK1/2-dependent manner. The protective function of CYLD deficiency was dependent on interferon gamma (IFN-γ) prestimulation of infected macrophages. Interestingly, the reduced NF-κB activation in CYLD-expressing macrophages limited the protective effect of IFN-γ by reducing NF-κB-dependent signal transducers and activators of transcription-1 (STAT1) activation. Taken together, our study identifies CYLD as an important inhibitor of RIPK2-dependent antibacterial immune responses in macrophages.

Indexed as

antibacterial immune responsesCYLDListeria monocytogenesmacrophagesreceptor-interacting protein kinase-2

Identifiers

PMID26834734
PMCPMC4717182
OpenAlexW2221663503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.